Innovation

Animal Model for Ovarian Cancer Cell Line

University of Kansas
posted on 06/07/2006

Ten (10) clonal lines from mouse ovarian surface epithelium of C57B6 mice.

Suggested Uses

* Ovarian cancer research * Therapeutics

Innovation Details
 

Detailed Description

A faculty member has developed ten (10) clonal lines from mouse ovarian surface epithelium of C57B6 mice.

We are interested in licensing these celllines to companies engaged in ovarian cancer research and/or form a collaboration to study the early detection and mouse gene therapy of this disease (see below for licensing instructions).
  • Tumorigenic mouse ovarian surface epithelial cells
  • Syngeneic immune-intact mouse model of ovarian cancer
Mouse ovarian surface epithelial cells (MOSEC; C57Bl6 mouse) were isolated and cultured in vitro and underwent spontaneous transformation after multiple passage. The parental cell line was cloned and 10 lines were established (1).All ten cell lines form tumors when injected into mice. Following intraperitoneal injection into C57Bl6 mice tumors seed throughout the peritoneal cavity and ascites fluids accumulate similar to late stage ovarian cancer in women.

Histopathologic analysis of tumors revealed a highly malignant neoplasm containing both carcinomatous and sarcomatous components.

Cell lines are:
IC5
ID5
ID8
ID9
IF5
IG10
2C6
2C12
3E3
3B11

1. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21(4):585-591.

For more information, please download the article below.

This project was supported by an RO1 grant from the NIH-NCI CA50616

File Number: 97KUMC162 

Other Information: *State of Development* Available for non-exclusive license. *Testing* Injection of these cells intraperitioneally into either nude or syngenic mice induced the formation of bloody ascites with seeding tumors throughout the peritoneal cavity.

The mice die within 2-3 months after a single injection. There is no evidence of disease until ascites formation at approximately one (1) week prior to death.

In tests for tumorigenicity, all ten (10) cell lines were malignant and produced bloody ascites within 2-5 months.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Elaine Spielbusch at University of Kansas for more information.

request more info
People

Case Manager:

Icon_avatar Elaine Spielbusch

Innovations (2)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

3,936 members 11,904 innovations 107 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...